Recon: Walmart to settle opioid suits for $3.1B; Immunogen lands accelerated approval for ovarian cancer drug

• Walmart to Pay $3.1 Billion to Settle Opioid Lawsuits (WSJ)
• AEYE Health gets FDA approval to screen diabetics to prevent blindness (Reuters)
• Immunogen's $6,220 ovarian cancer drug to be shipped within days (Reuters) (STAT) (FDA)
• U.S. FDA staff flags unclear benefits of Ardelyx's kidney disease drug (Reuters)
• FDA warns of rise in reports of child poisonings linked to cough medicine (NBC)
• AbbVie agrees to pay $54.4 mln in antitrust case over Alzheimer's drug (Reuters)
• Frustrations Grow Over Company’s Response to Breathing Device Recalls (NYTimes)

• Big pharma not doing enough to improve drug access – analysis (Reuters) (STAT)
• Looming obesity drug rivalry not a concern for Novo CEO (Reuters)
• Indonesia leader says intellectual property waiver must be widened on health issues (Reuters)
• Australia recommends against fifth vaccine dose as fresh COVID wave builds (Reuters)
• Japan's Daiichi Sankyo says mRNA COVID vaccine successful in booster trial (Reuters)
• ‘A very worrying scenario’: Internal documents on India Covid-19 vaccine raise troubling questions about approval process (STAT)

• Arcutis Biotherapeutics' skin disease cream meets main goal in late-stage study (Reuters)
• US FDA Collects ‘Majority’ Of PDUFA Program Fees After Payment Plea (Pink Sheet)
• Novo Nordisk, GSK pause some Twitter ad spending after Musk takeover (Endpoints)
• Adamis, Harpoon, Neoleukin and Tricida add to biotech layoff wave as pipeline setbacks spur cuts (Fierce)
• Horizon doubles down on Krystexxa marketing to physicians with ‘green stuff’ imagery (Endpoints)
• Sellas retunes leukemia trial as patients live longer than expected. Is the biotech's drug behind survival boost? (Fierce)
• GSK's antibiotics strategy scores 2nd win this month with phase 2 TB data (Fierce)
• The crew that sold its lead IL-2 program to Roche is back with $93M to work on more next-gen I/O drugs (Endpoints)
• Can an oncolytic virus therapy challenge the standard of care in bladder cancer? CG Oncology has $120M to find out (Endpoints)
• Roche doubles down on Jnana's drug discovery platform, kicking off second deal with $50M cash — while biotech bags $107M (Endpoints)

• Illumina cuts workforce by 5% amid supply chain woes, sales slowdown (MedtechDive)
• FDA Official Lists Four Regulatory Considerations For Connected Combination Products (MedtechInsight)
• Pear Therapeutics undergoes another round of layoffs, cutting 22% of staff (MedtechDive)
• ResMed, Google sibling Verily form digital health venture to improve access to sleep treatment (MedtechDive)
• UK Has ‘Much Room For Improvement’ On Genomic Testing Access (MedtechInsight)

• The FDA has banned certain vapes and medicines. We still bought these 13 products in its backyard (STAT)